
Full profile: /officials/T000490
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
8 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-06-05
Source: Congress.gov
Currently in
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025 This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage. The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply. Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Bills by the same sponsor or covering overlapping subjects.